Syntara Limited (SNT.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Gary Jonathan Phillips BPharm, MBA | CEO, MD & Director | 664.99k | -- | 1961 |
| Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. | Head of Drug Discovery | 469.35k | -- | 1964 |
| Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin | Head of Medical & Regulatory Affairs - Alliance Management | 318.83k | -- | 1972 |
| Dr. Jana Baskar | Chief Medical Officer | 416.96k | -- | -- |
| Mr. Timothy Luscombe B.Com., C.A. | Chief Financial Officer | -- | -- | -- |
| Mr. Cameron David Billingsley BA, LLB (Hons.) | Company Secretary & General Counsel | -- | -- | 1977 |
| Dr. Dieter Hamprecht | Head of Chemistry | -- | -- | -- |
Syntara Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 21
Description
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company's lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson's disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Corporate Governance
Upcoming Events
July 28, 2025 at 12:21 AM UTC - August 1, 2025 at 12:21 AM UTC
Syntara Limited Earnings Date
Recent Events
Recent Events Information Not Available